Detail akcie Mar LfSci Hldg Rg-A online

Business Summary: Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Maravai Lifesciences Holdings Inc revenues decreased 33% to $135.9M. Net loss decreased 20% to $95.1M. Revenues reflect Nucleic Acid Production segment decrease of 45% to $85.3M, Asia Pacific segment decrease of 60% to $27.1M, North America segment decrease of 15% to $84.9M. Lower net loss reflects Goodwill impairment decrease of 72% to $42.9M (expense).